Teladoc Health Reports First Quarter 2026 Results
Rhea-AI Summary
Teladoc Health (NYSE: TDOC) reported First Quarter 2026 results: revenue $613.8M (down 2% YoY), net loss $63.8M (or $0.36/share), and adjusted EBITDA $58.2M (flat YoY). Integrated Care revenue rose 2% to $395.4M; BetterHelp revenue fell 9% to $218.4M. Company reaffirmed full‑year outlook ranges for 2026.
Positive
- Integrated Care revenue +2% to $395.4M
- Consolidated adjusted EBITDA essentially flat at $58.2M
- International revenue +17% to $122.3M
- Company reaffirmed midpoint of full‑year 2026 guidance
Negative
- Consolidated revenue down 2% YoY to $613.8M
- BetterHelp revenue down 9% to $218.4M
- BetterHelp adjusted EBITDA down 75% to $1.9M (0.9% margin)
- Net loss $63.8M and free cash flow outflow $26.3M
- Capex increased to $35.8M for Q1 2026
News Market Reaction – TDOC
On the day this news was published, TDOC gained 1.85%, reflecting a mild positive market reaction. Argus tracked a trough of -9.9% from its starting point during tracking. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $20M to the company's valuation, bringing the market cap to $1.07B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TDOC was up 2.56% pre‑earnings from a depressed base, while key peers were mixed: GDRX +1.31%, SDGR +5.43%, OMCL +0.84%, PHR -2.59%, CERT -0.97%. Momentum scans only flagged PHR, suggesting today’s setup was company‑specific rather than a broad health‑IT move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Quarterly earnings | Neutral | +15.1% | Q4 2025 revenue flat, losses and lower full-year adjusted EBITDA with 2026 outlook. |
| Oct 29 | Quarterly earnings | Negative | +6.2% | Q3 2025 revenue and adjusted EBITDA declined with ongoing BetterHelp weakness. |
| Jul 29 | Quarterly earnings | Neutral | -1.7% | Q2 2025 mixed results, revenue down but net loss sharply improved year over year. |
| Apr 30 | Quarterly earnings | Negative | -2.8% | Q1 2025 revenue decline and goodwill impairment weighed on overall results. |
| Feb 26 | Annual earnings | Negative | -13.6% | Full-year 2024 revenue decline and large BetterHelp-related goodwill impairment. |
Earnings have often produced sizable moves, with negative or mixed fundamentals sometimes met with positive reactions, especially when losses narrow or guidance is stable.
Over the last five earnings cycles, Teladoc has reported modest revenue declines but steady Integrated Care growth and persistent BetterHelp pressure. Results frequently include net losses and non‑cash items such as goodwill impairments, alongside solid adjusted EBITDA. Price reactions have ranged from double‑digit drops to strong rallies, indicating investors focus on loss trajectory, segment mix, and guidance rather than revenue alone. Today’s Q1 2026 report continues the pattern of Integrated Care growth, BetterHelp softness, and stable adjusted EBITDA.
Historical Comparison
In the last five earnings reports, TDOC’s average move was about 0.64%, with reactions ranging from steep declines on large impairments to rallies when losses narrowed and guidance held steady.
Recent earnings show recurring revenue contraction, but Integrated Care has grown modestly while BetterHelp remains pressured, keeping adjusted EBITDA positive but constraining overall growth.
Market Pulse Summary
This announcement highlights Q1 2026 revenue of $613.8M (down 2% year over year) with net loss improving to $63.8M and adjusted EBITDA essentially flat at $58.2M. Integrated Care grew while BetterHelp declined, and free cash flow was a $26.3M outflow. Compared with prior earnings, the story remains one of segment mix shifts and disciplined cost control. Investors may watch revenue trends, cash generation, and BetterHelp stabilization in upcoming quarters.
Key Terms
adjusted EBITDA financial
goodwill impairment financial
free cash flow financial
restricted stock units financial
performance stock units financial
Schedule 13G regulatory
Form 4 regulatory
AI-generated analysis. Not financial advice.
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 (“First Quarter 2026”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2025 (“First Quarter 2025”).
Highlights
- First Quarter 2026 revenue of
$613.8 million , down2% year-over-year - First Quarter 2026 net loss of
$63.8 million , or$0.36 per share - First Quarter 2026 adjusted EBITDA of
$58.2 million , essentially flat year-over-year - Integrated Care segment revenue of
$395.4 million , up2% year-over-year, and adjusted EBITDA margin of14.2% - BetterHelp segment revenue of
$218.4 million , down9% year-over-year, and adjusted EBITDA margin of0.9% - The Company reaffirmed the midpoint of its full year financial outlook
“We delivered a good start to 2026, with first quarter consolidated revenue and adjusted EBITDA exceeding the midpoint of our guidance ranges, and our full-year outlooks for both segments remain on track,” said Chuck Divita, Chief Executive Officer of Teladoc Health. “Integrated Care delivered solid results in the quarter and we continued to make meaningful progress scaling insurance acceptance in BetterHelp.”
“We remain focused on disciplined execution across our strategic priorities, including key investments in product innovation, technology, and our clinical model. We see a meaningful opportunity to build on the unique strengths of our platform to deliver measurable and differentiated value for our clients and members and to return the business to growth. The progress we’re seeing strengthens our conviction in that path and we remain committed to driving long-term value for all stakeholders.”
| Key Financial Data | ||||||||||
| (In thousands, except per share data, unaudited) | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | Change | ||||||||
| Revenue | $ | 613,845 | $ | 629,369 | (2 | )% | ||||
| Net loss | $ | (63,837 | ) | $ | (93,012 | ) | 31 | % | ||
| Net loss per share | $ | (0.36 | ) | $ | (0.53 | ) | 32 | % | ||
| Adjusted EBITDA (1) | $ | 58,169 | $ | 58,093 | — | % | ||||
See note (1) in the Notes section that follows.
First Quarter 2026
Revenue decreased
Integrated Care segment revenue increased
Net loss totaled
Results for First Quarter 2025 included a non-cash goodwill impairment charge of
The non-cash goodwill impairment charge recorded in First Quarter 2025 was the result of the fair value of the Integrated Care segment being less than its carrying value at the time of the acquisition of Catapult Health, LLC.
Adjusted EBITDA(1) of
Capex and Cash Flow
Cash flow from operations was
Financial Outlook
The outlook provided below is based on current market conditions and expectations and what we know today.
| For the full year of 2026, we expect: | |
| Full Year 2026 Outlook Range | |
| Revenue | |
| Adjusted EBITDA | |
| Net loss per share | ( |
| Free Cash Flow | |
| U.S. Integrated Care Members (2) | 97 - 100 million |
| Integrated Care | |
| Revenue growth percentage (year-over-year) | |
| Adjusted EBITDA margin | |
| BetterHelp | |
| Revenue growth percentage (year-over-year) | ( |
| Adjusted EBITDA margin | |
| For the second quarter of 2026, we expect: | |
| 2Q 2026 Outlook Range | |
| Revenue | |
| Adjusted EBITDA | |
| Net loss per share | ( |
| U.S. Integrated Care Members (2) | 98.5 - 100 million |
| Integrated Care | |
| Revenue growth percentage (year-over-year) | ( |
| Adjusted EBITDA margin | |
| BetterHelp | |
| Revenue growth percentage (year-over-year) | ( |
| Adjusted EBITDA margin | ( |
See note (2) in the Notes section that follows.
Earnings Conference Call
The First Quarter 2026 earnings conference call and webcast will be held Wednesday, April 29, 2026 at 5:00 p.m. E.T. The conference call can be accessed by dialing (800) 715-9871 for U.S. participants and using the conference ID # 2214924. For international participants, please visit the following link for global dial-in numbers, using the same conference ID # 2214924: https://registrations.events/directory/international/itfs.html. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at www.teladochealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, the information under the caption “Financial Outlook” and statements we make regarding future financial or operating results, future numbers of members, BetterHelp paying users or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, initiatives to improve our efficiency and competitiveness, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; (viii) the success of our initiatives to improve our efficiency and competitiveness; and (ix) imposed and threatened tariffs by the United States and its trading partners, and any resulting disruptions or inefficiencies in our supply chain. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
| TELADOC HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data, unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Revenue | $ | 613,845 | $ | 629,369 | |||
| Costs and expenses: | |||||||
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 197,526 | 196,829 | |||||
| Advertising and marketing | 151,527 | 168,185 | |||||
| Sales | 51,276 | 48,693 | |||||
| Technology and development | 67,865 | 69,958 | |||||
| General and administrative | 102,093 | 112,774 | |||||
| Goodwill impairment | — | 59,138 | |||||
| Acquisition, integration, and transformation costs | 1,064 | 2,188 | |||||
| Restructuring costs | 11,975 | 4,347 | |||||
| Amortization of intangible assets | 89,826 | 84,304 | |||||
| Depreciation of property and equipment | 2,461 | 3,564 | |||||
| Total costs and expenses | 675,613 | 749,980 | |||||
| Loss from operations | (61,768 | ) | (120,611 | ) | |||
| Interest income | (6,490 | ) | (12,674 | ) | |||
| Interest expense | 5,368 | 5,765 | |||||
| Other expense (income), net | 196 | (2,435 | ) | ||||
| Loss before provision for income taxes | (60,842 | ) | (111,267 | ) | |||
| Provision for income taxes | 2,995 | (18,255 | ) | ||||
| Net loss | $ | (63,837 | ) | $ | (93,012 | ) | |
| Net loss per share, basic and diluted | $ | (0.36 | ) | $ | (0.53 | ) | |
| Weighted-average shares used to compute basic and diluted net loss per share | 179,122,268 | 174,154,128 | |||||
Stock-based Compensation Summary
Compensation expense for stock-based awards was classified as follows (in thousands, unaudited):
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately) | $ | 347 | $ | 573 | |||
| Advertising and marketing | 860 | 1,503 | |||||
| Sales | 2,077 | 4,259 | |||||
| Technology and development | 2,727 | 5,785 | |||||
| General and administrative | 8,600 | 13,043 | |||||
| Total stock-based compensation expense (3) | $ | 14,611 | $ | 25,163 | |||
See note (3) in the Notes section that follows.
Revenues
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| (In thousands, unaudited) | 2026 | 2025 | Change | |||||||
| Revenue by Type | ||||||||||
| Access Fees | $ | 484,655 | $ | 525,736 | (8 | )% | ||||
| Other | 129,190 | 103,633 | 25 | % | ||||||
| Total Revenue | $ | 613,845 | $ | 629,369 | (2 | )% | ||||
| Revenue by Geography | ||||||||||
| U.S. | $ | 491,505 | $ | 524,970 | (6 | )% | ||||
| International | 122,340 | 104,399 | 17 | % | ||||||
| Total Revenue | $ | 613,845 | $ | 629,369 | (2 | )% | ||||
Summary Operating Metrics
Consolidated
| Three Months Ended | ||||||||
| March 31, | ||||||||
| (In millions) | 2026 | 2025 | Change | |||||
| Total Visits | 4.4 | 4.4 | (2 | )% | ||||
Integrated Care
| As of March 31, | ||||||||
| (In millions) | 2026 | 2025 | Change | |||||
| U.S. Integrated Care Members (2) | 101.2 | 102.5 | (1 | )% | ||||
| Chronic Care Program Enrollment (4) | 1.197 | 1.151 | 4 | % | ||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | Change | ||||||||
| Average Monthly Revenue Per U.S. Integrated Care Member (5) | $ | 1.30 | $ | 1.27 | 2 | % | ||||
BetterHelp
| Average for | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| (In millions) | 2026 | 2025 | Change | |||||
| BetterHelp Paying Users (6) | 0.361 | 0.397 | (9 | )% | ||||
See notes (2), (4), (5), and (6) in the Notes section that follows.
Operating Results by Segment (see note (7) in the Notes section that follows)
The following table presents operating results by reportable segment for the periods indicated:
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| (In thousands, unaudited) | 2026 | 2025 | Change | |||||||
| Integrated Care | ||||||||||
| Revenue | $ | 395,445 | $ | 389,468 | 2 | % | ||||
| Adjusted EBITDA | $ | 56,277 | $ | 50,379 | 12 | % | ||||
| Adjusted EBITDA Margin % | 14.2 | % | 12.9 | % | ||||||
| BetterHelp | ||||||||||
| Consumer and Other | $ | 205,463 | $ | 239,901 | (14 | )% | ||||
| Insurance Covered Services | 12,937 | — | n/a | |||||||
| Total Revenue | $ | 218,400 | $ | 239,901 | (9 | )% | ||||
| Adjusted EBITDA | $ | 1,892 | $ | 7,714 | (75 | )% | ||||
| Adjusted EBITDA Margin % | 0.9 | % | 3.2 | % | ||||||
n/a - not applicable
| TELADOC HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (63,837 | ) | $ | (93,012 | ) | |
| Adjustments to reconcile net loss to net cash flows from operating activities: | |||||||
| Goodwill impairment | — | 59,138 | |||||
| Amortization of intangible assets | 89,826 | 84,304 | |||||
| Stock-based compensation | 14,611 | 25,163 | |||||
| Depreciation of property and equipment | 2,461 | 3,564 | |||||
| Amortization of right-of-use assets | 1,898 | 2,305 | |||||
| Provision for allowances for doubtful accounts | (79 | ) | 59 | ||||
| Deferred income taxes | (1,060 | ) | (26,865 | ) | |||
| Other, net | 1,329 | 1,753 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (20,996 | ) | (15,270 | ) | |||
| Prepaid expenses and other current assets | (29,446 | ) | (23,786 | ) | |||
| Inventory | 6,315 | 1,515 | |||||
| Other assets | 336 | 412 | |||||
| Accounts payable | (2,108 | ) | 17,356 | ||||
| Accrued expenses and other current liabilities | 39,114 | 12,568 | |||||
| Accrued compensation | (31,529 | ) | (21,463 | ) | |||
| Deferred revenue | 5,060 | (5,542 | ) | ||||
| Operating lease liabilities | (2,297 | ) | (2,482 | ) | |||
| Other liabilities | (82 | ) | (3,798 | ) | |||
| Net cash provided by operating activities | 9,516 | 15,919 | |||||
| Cash flows from investing activities: | |||||||
| Capital expenditures | (1,660 | ) | (2,726 | ) | |||
| Capitalized software development costs | (34,162 | ) | (28,859 | ) | |||
| Acquisitions accounted for as business combinations, net of cash acquired | — | (64,608 | ) | ||||
| Payments for investments | (700 | ) | (27,075 | ) | |||
| Net cash used in investing activities | (36,522 | ) | (123,268 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from the exercise of stock options | — | 80 | |||||
| Proceeds from employee stock purchase plan | 399 | 689 | |||||
| Other, net | (2,848 | ) | — | ||||
| Net cash (used in) provided by financing activities | (2,449 | ) | 769 | ||||
| Net decrease in cash and cash equivalents | (29,455 | ) | (106,580 | ) | |||
| Effect of foreign currency exchange rate changes | (891 | ) | 1,585 | ||||
| Cash and cash equivalents at beginning of the period | 781,084 | 1,298,327 | |||||
| Cash and cash equivalents at end of the period | $ | 750,738 | $ | 1,193,332 | |||
| TELADOC HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data, unaudited) | |||||||
| March 31, 2026 | December 31, 2025 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 750,738 | $ | 781,084 | |||
| Accounts receivable, net of allowance for doubtful accounts of | 213,627 | 192,826 | |||||
| Inventories | 31,557 | 38,203 | |||||
| Prepaid expenses and other current assets | 136,417 | 107,016 | |||||
| Total current assets | 1,132,339 | 1,119,129 | |||||
| Property and equipment, net | 26,278 | 26,972 | |||||
| Goodwill | 283,190 | 283,190 | |||||
| Intangible assets, net | 1,235,185 | 1,297,087 | |||||
| Operating lease—right-of-use assets | 24,233 | 26,119 | |||||
| Other assets | 106,036 | 105,803 | |||||
| Total assets | $ | 2,807,261 | $ | 2,858,300 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 45,196 | $ | 47,967 | |||
| Accrued expenses and other current liabilities | 233,292 | 198,208 | |||||
| Accrued compensation | 60,668 | 96,258 | |||||
| Deferred revenue, current | 65,714 | 62,305 | |||||
| Total current liabilities | 404,870 | 404,738 | |||||
| Operating lease liabilities, net of current portion | 31,738 | 34,204 | |||||
| Deferred revenue, net of current portion | 10,365 | 9,139 | |||||
| Deferred taxes, net | 27,610 | 28,945 | |||||
| Convertible senior notes, net | 995,811 | 994,925 | |||||
| Other liabilities | 551 | 643 | |||||
| Total liabilities | 1,470,945 | 1,472,594 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Common stock, | 180 | 178 | |||||
| Additional paid-in capital | 17,865,617 | 17,850,478 | |||||
| Accumulated deficit | (16,494,059 | ) | (16,430,222 | ) | |||
| Accumulated other comprehensive loss | (35,422 | ) | (34,728 | ) | |||
| Total stockholders’ equity | 1,336,316 | 1,385,706 | |||||
| Total liabilities and stockholders’ equity | $ | 2,807,261 | $ | 2,858,300 | |||
Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we use certain non-GAAP financial measures to clarify and enhance an understanding of past performance, which include adjusted EBITDA and free cash flow. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance, and are commonly used by investors to evaluate our performance and that of our competitors. We further believe that these financial measures are useful to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows. We use these non-GAAP financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.
Adjusted EBITDA consists of net loss before provision for income taxes; other expense (income), net; interest income; interest expense; depreciation of property and equipment; amortization of intangible assets; restructuring costs; acquisition, integration, and transformation cost; goodwill impairments; and stock-based compensation.
Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.
Our use of these non-GAAP terms may vary from that of others in our industry, and other companies may calculate such measures differently than we do, limiting their usefulness as comparative measures.
Non-GAAP measures have important limitations as analytical tools and you should not consider them in isolation, and they should not be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other measures derived in accordance with GAAP. Some of these limitations are:
- adjusted EBITDA eliminates the impact of the provision for income taxes on our results of operations, and does not reflect other expense (income), net, interest income, or interest expense;
- adjusted EBITDA does not reflect restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;
- adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration, and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration, and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our enterprise resource planning system. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but, rather, incremental costs incurred in connection with our acquisition and integration activities;
- adjusted EBITDA does not reflect goodwill impairment charges; and
- adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.
In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being amortized and depreciated will often have to be replaced in the future, and adjusted EBITDA does not reflect any expenditures for such replacements.
We compensate for these limitations by using these non-GAAP measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.
In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to adjusted EBITDA:
| Reconciliation of GAAP Net Loss to Adjusted EBITDA (In thousands, unaudited) | |||||||||||
| Outlook in millions (8) | |||||||||||
| Three Months Ended March 31, | Second Quarter | Full Year | |||||||||
| 2026 | 2025 | 2026 | 2026 | ||||||||
| Net loss | $ | (63,837 | ) | $ | (93,012 | ) | |||||
| Add: | |||||||||||
| Provision for income taxes | 2,995 | (18,255 | ) | ||||||||
| Other expense (income), net | 196 | (2,435 | ) | ||||||||
| Interest expense | 5,368 | 5,765 | |||||||||
| Interest income | (6,490 | ) | (12,674 | ) | |||||||
| Depreciation of property and equipment | 2,461 | 3,564 | |||||||||
| Amortization of intangible assets | 89,826 | 84,304 | |||||||||
| Restructuring costs | 11,975 | 4,347 | |||||||||
| Acquisition, integration, and transformation costs | 1,064 | 2,188 | |||||||||
| Goodwill impairment | — | 59,138 | |||||||||
| Stock-based compensation | 14,611 | 25,163 | |||||||||
| Total Adjustments | 122,006 | 151,105 | 91 - 121 | 403 - 496 | |||||||
| Consolidated Adjusted EBITDA | $ | 58,169 | $ | 58,093 | |||||||
| Segment Adjusted EBITDA | |||||||||||
| Integrated Care | $ | 56,277 | $ | 50,379 | |||||||
| BetterHelp | 1,892 | 7,714 | |||||||||
| Consolidated Adjusted EBITDA | $ | 58,169 | $ | 58,093 | |||||||
See note (8) in the Notes section that follows.
The following is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow:
| Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow (In thousands, unaudited) | |||||||||
| Three Months Ended | Outlook (9) | ||||||||
| March 31, | Full Year | ||||||||
| 2026 | 2025 | 2026 (in millions) | |||||||
| Net cash provided by operating activities | $ | 9,516 | $ | 15,919 | |||||
| Capital expenditures | (1,660 | ) | (2,726 | ) | |||||
| Capitalized software development costs | (34,162 | ) | (28,859 | ) | |||||
| Capex | (35,822 | ) | (31,585 | ) | (130) - (120) | ||||
| Free Cash Flow | $ | (26,306 | ) | $ | (15,666 | ) | |||
See note (9) in the Notes section that follows.
Notes:
- A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these non-GAAP measures is also included under the heading “Non-GAAP Financial Measures.”
- U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.
- Excluding the amount capitalized related to software development projects.
- Chronic Care Program Enrollment represents the total number of enrollees across our suite of chronic care programs at the end of the applicable period.
- Average monthly revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 2) during the applicable period.
- BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy and psychiatry services during the applicable period, including both those who pay directly out-of-pocket and those who utilize their insurance coverage.
- We have two segments: Integrated Care and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis. Within the BetterHelp segment, Consumer and Other primarily includes revenue from BetterHelp Paying Users that pay for services directly out-of-pocket while Insurance Covered Services reflects revenue from BetterHelp Paying Users that utilize insurance coverage to pay for services, which includes any copayments.
- We have not provided a full line-item reconciliation for net loss to adjusted EBITDA outlook because we do not provide outlook on the individual reconciling items between net loss and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as impairments, stock-based compensation and the related tax impact, provision for income taxes, acquisition, integration, and transformation costs, and restructuring costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure outlook is not available without unreasonable effort.
- We have not provided a line-item reconciliation for free cash flow to net cash from operating activities for this future period because we believe such a reconciliation would imply a degree of precision and certainty that could be confusing to investors and we are unable to reasonably predict certain items contained in the GAAP measure without unreasonable effort.
Investors:
Michael Minchak
617-444-9612
ir@teladochealth.com
Media:
Lou Serio
202-569-9715
pr@teladochealth.com
